The Federal Reserve’s open market committee left interest rates unchanged on Wednesday, leaving them at 5.25% to 5.5%. That sent 10-year Treasury note rates down, regenerating investor interest in equities.

In early trading on Thursday, the Dow Jones industrials are up about 0.5%, the S&P 500 is up about 0.7% and the Nasdaq Composite is up about 1.1%.

Here’s a look at some of today’s market movers.

Starbucks

Before markets opened on Thursday, Starbucks Corp. (NASDAQ: SBUX) reported fiscal fourth-quarter results that beat consensus estimates on both the top and bottom lines.

	Estimate	Actual	Surprise
Revenue ($B)	9.29	9.37	0.9%
Adj EPS	0.81	1.06	11.1%

Fourth-quarter revenue reached a new all-time high on a same-store sales increase of 8% year over year. The average ticket rose 4% and total transactions rose 3%. Bigger price increases in North America lifted the average ticket by 6% and transactions by 2%.

International same-store sales rose 5%, the same as China’s increase. The average ticket was down 1% internationally ‌and down 3% in China. Transactions picked up the slack, rising by 6% internationally and 8% in China.

In its initial outlook for the 2024 fiscal year, Starbucks said on its conference call that it expects recent momentum in China to continue. The company sees same-store sales rising by 4% to 6% in the first half of the fiscal year. Global and U.S. same-store sales were forecast to increase by 5% to 7% for the full year. (These are America’s most trusted food & drink brands.)

Starbucks expects its store count to rise by 7% globally, including a U.S. increase of 4% and 13% growth in China.

Shortly after Thursday’s opening bell, Starbucks stock traded up 11%, at $101.37 in a 52-week range of $82.97 to $115.48.

Qualcomm

After markets closed Wednesday, Qualcomm Corp. (NASDAQ: QCOM) also reported EPS and revenue that topped estimates. Year over year, revenue fell 23.9% and EPS dropped from $3.13 in the year-ago quarter to $2.02.

	Estimate	Actual	Surprise
Revenue ($B)	8.51	8.67	1.8%
Adj EPS	1.91	2.02	5.8%

On its conference call, Qualcomm said calendar year handset sales for 2023 will fall by mid-to-high single digits, somewhat better than its earlier estimate. (U.S.-China trade wars: How nine imports threaten U.S. national security.)

Qualcomm also pointed at the AI on-device market as a potential requirement for mobile device OEMs. Without naming names, the company believes its new Snapdragon chip is a solid challenger to Apple’s latest mobile and desktop/laptop chips.

Shares traded up 6.4% early Thursday morning at around $118.00 in a 52-week range of $101.47 to $139.94.

SolarEdge

SolarEdge Technologies Inc. (NASDAQ: SEDG) designs, makes and sells inverter systems for solar PV systems. Since mid-July, SolarEdge stock has declined by more than 70%. When it reported third-quarter results late Wednesday, the company missed on both EPS and revenue estimates.

	Estimate	Actual	Surprise
Revenue ($M)	769.2	725.3	-5.7%
Adj EPS	0.83	0.55	-33.7%

Adding to the misery, SolarEdge issued downside guidance for the fourth quarter. The company sees revenue of $300 to $350 million, compared to the previous analysts’ consensus estimate for revenue of $715.2 million.

SolarEdge stock is getting pummeled early Thursday, trading down more than 15% at the opening bell. After about half an hour, shares traded down about 5.7 $71.60. in a 52-week range of $63.25 to $345.80. The low was posted this morning.

Moderna

Moderna Inc. (NASDAQ: MRNA), developer of the COVID-19 vaccine Spikevax, reported a much larger than forecast per-share loss Thursday morning, side by side with a solid beat on the revenue estimate.

	Estimate	Actual	Surprise
Revenue ($B)	1.38	1.83	33.2%
Adj EPS	-1.93	-9.53	-393.8%

Thinking ahead (way ahead), the company said it expects fiscal 2024 sales of about $4 billion and the return of organic sales growth in 2025. The company reported $12.8 billion in cash and other liquidity, a decline of $2 billion since the end of the second quarter. In its remarks about the future, Moderna said it expects a cash balance at the end of 2024 of around $9 billion. At the end of 2025, the cash balance is likely to dip to a range of $6 to $7 billion. This is not good news for investors. (These are the youngest members of the Fortune 500.)

Moderna stock was hammered early Thursday, trading down about 6%, at $71.63 in a 52-week range of $62.55 to $217.25. The low was posted early this morning.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.